Document is current
Any future updates will be listed below
-
Authors
Hillen, Christoph
Sachs, Charlotte
Jaeger, Anna
Prieske, Katharina
Schmalfeldt, Barbara
Lütgehetmann, Marc
Sterneck, Martina
Kluger, Malte A.
Kaufmann, Andreas M.
Vettorazzi, Eik
Woelber, Linn
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 14 October 2023
Accepted: 20 May 2025
First Online: 3 July 2025
Declarations
:
: The Hamburg Medical Association Ethics Committee approved the study in June 2019 (Ethics vote: PV6011).
: The authors of this manuscript have conflicts of interest to disclose, L Woelber has given talks or received honoraria from Roche, Eisai, Novartis, MSD, Seagen, GSK, Astra Zeneca, Pfizer, Lumenis, TEVA, pomedicis, and Omniamed and has served as consultant or received consulting fees from GSK, Roche, Eisai, MSD, and Seagen. Her research was supported by grants from DKH, Hamburger Krebsgesellschaft, medac oncology, and Roche diagnostics. K Prieske reports personal fees from AstraZeneca, MSD, Molecular health, GSK, Roche, and Clovis Oncology outside the submitted work. However, the opinions expressed in this article are those of the authors and do not reflect those of any of the companies mentioned above.
